PD-1 antibodies and PD-L1 antibodies and uses thereof

• US 8,741,295 B2
• Filed: 02/09/2010
• Issued: 06/03/2014
• Est. Priority Date: 02/09/2009
• Status: Active Grant

• Current Assignee: Institute Paoli-Calmettes, Université d'Aix-Marseille
• Original Assignee: Inserm (institut national de la sant et de la recherche mdicale, Universite de la Mediterranee
• Inventors: Olive, Daniel
• Primary Examiner(s): KEMMERER, ELIZABETH
• Application Number:
  US13/148,420
• Publication Number:
  US 20120039906A1
• Time in Patent Office: 1,575 Days
• Field of Search: None
• US Class Current: 424/141.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.

Claims

1. A PD-L1 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4080 or I-4081.

2. A method for treating the human or animal body by therapy, comprising administering a PD-L1 antibody according to claim 1 to said human or animal body, wherein said treating is for an autoimmune disease, transplantation rejection or a graft versus host disease.

3. A hybridoma cell line selected from the group consisting of CNCM I-4122, CNCM I-4080 and CNCM I-4081.